| Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial S McCormack, DT Dunn, M Desai, DI Dolling, M Gafos, R Gilson, ... The Lancet 387 (10013), 53-60, 2016 | 2100 | 2016 |
| Global burden of human papillomavirus and related diseases D Forman, C de Martel, CJ Lacey, I Soerjomataram, J Lortet-Tieulent, ... Vaccine 30, F12-F23, 2012 | 2023 | 2012 |
| Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease CJN Lacey, CM Lowndes, KV Shah Vaccine 24, S35-S41, 2006 | 764* | 2006 |
| PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial S McCormack, G Ramjee, A Kamali, H Rees, AM Crook, M Gafos, ... The Lancet 376 (9749), 1329-1337, 2010 | 392 | 2010 |
| EUROGIN 2011 roadmap on prevention and treatment of HPV‐related disease M Arbyn, S De Sanjosé, M Saraiya, M Sideri, J Palefsky, C Lacey, ... International journal of cancer 131 (9), 1969-1982, 2012 | 327 | 2012 |
| 2012 European guideline for the management of anogenital warts CJN Lacey, SC Woodhall, A Wikstrom, J Ross Journal of the European Academy of Dermatology and Venereology 27 (3), e263-e270, 2013 | 283 | 2013 |
| Therapy for genital human papillomavirus-related disease CJN Lacey Journal of Clinical Virology 32, 82-90, 2005 | 276 | 2005 |
| The burden of human papillomavirus infections and related diseases in sub-saharan Africa H De Vuyst, L Alemany, C Lacey, CJ Chibwesha, V Sahasrabuddhe, ... Vaccine 31, F32-F46, 2013 | 262 | 2013 |
| Therapy of human papillomavirus-related disease PL Stern, SH van der Burg, IN Hampson, TR Broker, A Fiander, CJ Lacey, ... Vaccine 30, F71-F82, 2012 | 252 | 2012 |
| Prospects for control of herpes simplex virus disease through immunization LR Stanberry, AL Cunningham, A Mindel, LL Scott, SL Spruance, FY Aoki, ... Clinical Infectious Diseases 30 (3), 549-566, 2000 | 252 | 2000 |
| Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts CJN Lacey, RL Goodall, GR Tennvall, R Maw, GR Kinghorn, PG Fisk, ... Sexually Transmitted Infections 79 (4), 270-275, 2003 | 196 | 2003 |
| Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease F Chen, SL Day, RA Metcalfe, G Sethi, MS Kapembwa, MG Brook, ... Medicine 84 (2), 98-106, 2005 | 186 | 2005 |
| Estimation of the impact of genital warts on health-related quality of life S Woodhall, T Ramsey, C Cai, S Crouch, M Jit, Y Birks, WJ Edmunds, ... Sexually transmitted infections 84 (3), 161-166, 2008 | 185 | 2008 |
| European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts G Von Krogh, CJN Lacey, G Gross, R Barrasso, A Schneider Sexually transmitted infections 76 (3), 162-168, 2000 | 164 | 2000 |
| Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of … P Vandepapeliere, R Barrasso, CJLM Meijer, JMM Walboomers, ... The Journal of infectious diseases 192 (12), 2099-2107, 2005 | 158 | 2005 |
| British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008 A Fakoya, H Lamba, N Mackie, R Nandwani, A Brown, EJ Bernard, ... HIV medicine 9 (9), 681-720, 2008 | 153 | 2008 |
| Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts CJN Lacey, HSG Thompson, EF Monteiro, T O'neill, ML Davies, ... The Journal of infectious diseases 179 (3), 612-618, 1999 | 145 | 1999 |
| B ritish HIV Association guidelines for HIV‐associated malignancies 2014 Writing Group, M Bower, A Palfreeman, M Alfa‐Wali, C Bunker, F Burns, ... HIV medicine 15, 1-92, 2014 | 144 | 2014 |
| Analysis of the sociodemography of gonorrhoea in Leeds, 1989-93 CJN Lacey, DW Merrick, DC Bensley, I Fairley Bmj 314 (7096), 1715, 1997 | 139 | 1997 |
| A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH M Osman, A Mistry, A Keding, R Gabe, E Cook, S Forrester, R Wiggins, ... PLoS neglected tropical diseases 11 (5), e0005527, 2017 | 134 | 2017 |
